Report: Global Pharmaceutical & Biotechnology Outlook 2013: Mature Biotech Report Insights (Continued)
• However in-licensing of early or mid stage compounds or small acquisitions will continue since the rising stars will keep throwing the bait by taking risks and innovate using novel technology platforms or validating novel targets for treating diseases • Patent expiry impact is modest for the next five years for the sector as majority have not so easy to copy biologics and other drugs in their portfolio • The optimism of biosimilar players is reflected in the maturing pipeline • Para IV filing from other generic players continues to pour leaving room for surprises and volatility www.researchonglobalmarkets.com